Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2002 1
2005 3
2006 2
2007 4
2010 2
2012 1
2013 2
2014 6
2015 9
2016 10
2017 11
2018 10
2019 2
2020 6
2021 5
2022 7
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25490444

75 results

Results by year

Filters applied: . Clear all
Page 1
CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy.
Jin HS, Ko M, Choi DS, Kim JH, Lee DH, Kang SH, Kim I, Lee HJ, Choi EK, Kim KP, Yoo C, Park Y. Jin HS, et al. Cancer Immunol Res. 2020 Jul;8(7):912-925. doi: 10.1158/2326-6066.CIR-19-0877. Epub 2020 Apr 7. Cancer Immunol Res. 2020. PMID: 32265229
CD226 opposes TIGIT to disrupt Tregs in melanoma.
Fourcade J, Sun Z, Chauvin JM, Ka M, Davar D, Pagliano O, Wang H, Saada S, Menna C, Amin R, Sander C, Kirkwood JM, Korman AJ, Zarour HM. Fourcade J, et al. JCI Insight. 2018 Jul 26;3(14):e121157. doi: 10.1172/jci.insight.121157. eCollection 2018 Jul 26. JCI Insight. 2018. PMID: 30046006 Free PMC article.
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH. Josefsson SE, et al. Clin Cancer Res. 2018 Feb 15;24(4):870-881. doi: 10.1158/1078-0432.CCR-17-2337. Epub 2017 Dec 7. Clin Cancer Res. 2018. PMID: 29217528 Free PMC article.
Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype.
Wang B, Zhang W, Jankovic V, Golubov J, Poon P, Oswald EM, Gurer C, Wei J, Ramos I, Wu Q, Waite J, Ni M, Adler C, Wei Y, Macdonald L, Rowlands T, Brydges S, Siao J, Poueymirou W, MacDonald D, Yancopoulos GD, Sleeman MA, Murphy AJ, Skokos D. Wang B, et al. Sci Immunol. 2018 Nov 2;3(29):eaat7061. doi: 10.1126/sciimmunol.aat7061. Sci Immunol. 2018. PMID: 30389797
75 results